Human serum albumin binders: A piggyback ride for long-acting therapeutics

被引：17
作者：
Ullah, Aziz [1 ,2 ]
Shin, Goeun [1 ,4 ]
Lim, Sung In [1 ,3 ]
机构：
[1] Pukyong Natl Univ, Dept Chem Engn, Busan 48513, South Korea
[2] Gomal Univ, Fac Pharm, Gomal Ctr Pharmaceut Sci, Dera Ismail Khan 29050, Khyber Pakhtunk, Pakistan
[3] Marine BioResource Co Ltd, 365 Sinseon Ro, Busan 48548, South Korea
[4] Nbios Inc, 7 Jukheon Gil, Gangneung Si, Gangwon Do, South Korea
来源：
DRUG DISCOVERY TODAY | 2023年 / 28卷 / 10期
基金：
新加坡国家研究基金会;
关键词：
serum albumin; half-life extension; drug delivery; albumin-binding domain; long-acting therapeutics; STREPTOCOCCAL PROTEIN-G; SINGLE-CHAIN DIABODY; FATTY-ACID-BINDING; HALF-LIFE; HIGH-AFFINITY; PHARMACOKINETIC PROPERTIES; DOMAIN ANTIBODIES; CRYSTAL-STRUCTURE; FUSION PROTEIN; RECEPTOR;
D O I：
10.1016/j.drudis.2023.103738
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Human serum albumin (HSA) is the most abundant protein in the blood and has desirable properties as a drug carrier. One of the most promising ways to exploit HSA as a carrier is to append an albumin-binding moiety (ABM) to a drug for in situ HSA binding upon administration. Nature-and library-derived ABMs vary in size, affinity, and epitope, differentially improving the pharmacokinetics of an appended drug. In this review, we evaluate the current state of knowledge regarding various aspects of ABMs and the unique advantages of ABM-mediated drug delivery. Furthermore, we discuss how ABMs can be specifically modulated to maximize potential benefits in clinical development.
引用
收藏
页数：16
相关论文
共 123 条
  • [1] Adabi Elham, 2017, Iranian Biomedical Journal, V21, P77, DOI 10.18869/acadpub.ibj.21.2.77
  • [2] Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides
    Adams, Ralph
    Joyce, Callum
    Kuravskiy, Mikhail
    Harrison, Katriona
    Ahdash, Zainab
    Balmforth, Matthew
    Chia, Kelda
    Marceddu, Cinzia
    Coates, Matthew
    Snowden, James
    Goursaud, Emmanuel
    Menochet, Karelle
    van den Elsen, Jean
    Payne, Richard J.
    Lawson, Alastair D. G.
    Scott-Tucker, Anthony
    Macpherson, Alex
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [3] Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life
    Adams, Ralph
    Griffin, Laura
    Compson, Joanne E.
    Jairaj, Mark
    Baker, Terry
    Ceska, Tom
    West, Shauna
    Zaccheo, Oliver
    Dave, Emma
    Lawson, Alastair D. G.
    Humphreys, David P.
    Heywood, Sam
    [J]. MABS, 2016, 8 (07) : 1336 - 1346
  • [4] Extending Serum Half-life of Albumin by Engineering Neonatal Fc Receptor ( FcRn) Binding
    Andersen, Jan Terje
    Dalhus, Bjorn
    Viuff, Dorthe
    Ravn, Birgitte Thue
    Gunnarsen, Kristin Stoen
    Plumridge, Andrew
    Bunting, Karen
    Antunes, Filipa
    Williamson, Rebecca
    Athwal, Steven
    Allan, Elizabeth
    Evans, Leslie
    Bjoras, Magnar
    Kjaerulff, Soren
    Sleep, Darrell
    Sandlie, Inger
    Cameron, Jason
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (19) : 13492 - 13502
  • [5] Cross-species Binding Analyses of Mouse and Human Neonatal Fc Receptor Show Dramatic Differences in Immunoglobulin G and Albumin Binding
    Andersen, Jan Terje
    Daba, Muluneh Bekele
    Berntzen, Goril
    Michaelsen, Terje E.
    Sandlie, Inger
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (07) : 4826 - 4836
  • [6] First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
    Baird, Richard D.
    Linossi, Constanza
    Middleton, Mark
    Lord, Simon
    Harris, Adrian
    Rodon, Jordi
    Zitt, Christof
    Fiedler, Ulrike
    Dawson, Keith M.
    Leupin, Nicolas
    Stumpp, Michael T.
    Harstrick, Andreas
    Azaro, Analia
    Fischer, Stefanie
    Omlin, Aurelius
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (02) : 145 - +
  • [7] Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide
    Bak, Mijeong
    Park, Junyong
    Min, Kiyoon
    Cho, Jinhwan
    Seong, Jihyoun
    Hahn, Young S.
    Tae, Giyoong
    Kwon, Inchan
    [J]. PHARMACEUTICS, 2020, 12 (04)
  • [8] Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat
    Bao, Weike
    Holt, Lucy J.
    Prince, Rob D.
    Jones, Gavin X.
    Aravindhan, Karpagam
    Szapacs, Mathew
    Barbour, April M.
    Jolivette, Larry J.
    Lepore, John J.
    Willette, Robert N.
    DeAngelis, Elena
    Jucker, Beat M.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2013, 12
  • [9] Preclinical evaluation of half-life extended Affimer® biotherapeutics targeting the PD-L1 pathway
    Basran, Amrik
    Jenkins, Emma
    Adam, Estelle
    Laurent, Floriane
    Writer, Michele
    Oumie, Assa
    Sivula, Jyrki
    West, Maureen
    Stanley, Emma
    Hillman, Jennifer
    Robles-munoz, Viviana
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [10] IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY
    Behrens, F.
    Taylor, P. C.
    Wetzel, D.
    Brun, N. C.
    Brandt-Juergens, J.
    Drescher, E.
    Dokoupilova, E.
    Rowinska-Osuch, A.
    Martin, N. Abdel-Kader
    de Vlam, K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 170 - 171
12345678910